# ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

> **NCT01009788** · PHASE2 · COMPLETED · sponsor: **Steven J Isakoff, MD, PhD** · enrollment: 63 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer
- BRCA1 Gene Mutation
- brca2 Gene Mutation

## Interventions

- **DRUG:** ABT-888
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT01009788
- **Lead sponsor:** Steven J Isakoff, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-09
- **Final completion:** 2015-09
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009788, "ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01009788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*